Navigation Links
Facet Biotech and Trubion Announce Worldwide Collaboration for the Development and Commercialization of TRU-016
Date:8/28/2009

ives of the Phase 1 TRU-016 CLL study were to define safety and tolerability, identify a maximum tolerated dose, evaluate pharmacology and pharmacodynamics, and assess preliminary clinical activity.

About Facet Biotech

Facet Biotech is a biotechnology company dedicated to advancing its pipeline of four clinical-stage products, leveraging its research and development capabilities to identify and develop new oncology drugs and applying its proprietary next-generation protein engineering technologies to potentially improve the clinical performance of protein therapeutics. Facet Biotech Corporation launched in December 2008 as a spin-off from PDL BioPharma, Inc.

Facet Forward-Looking Statements

This press release contains forward-looking statements of Facet Biotech, including regarding the possible utility of TRU-016 in indications other than CLL and the advancement of the clinical development of TRU-016. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from those, express or implied, in these forward-looking statements. Various factors may cause differences between current expectations and actual results. The development of TRU-016 could be adversely impacted by changes in Facet Biotech's and Trubion's development plans or timelines, including because of unexpected safety or efficacy data observed during clinical trials, enrollment rates in clinical trials, changes in expected competition and changes in regulatory support for the path towards registration. As a result, the clinical development of TRU-016 may not progress as expected or at all. The results observed to date in clinical trials of TRU-016 in CLL may not be predictive of results to be obtained in the additional evaluations and studies that would be necessary to demonstrate TRU-016 to be safe and effective in the treatment of patients with CLL or any other indication. Other fa
'/>"/>

SOURCE Trubion Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. Facet Solutions Completes 1 Year Follow-up on U.S. Pilot Study
2. The Help Group Launches Multifaceted Autism Awareness Campaign
3. Perrigo Announces FDA Approval for Sulfacetamide Sodium Topical Suspension USP, 10% (Lotion)
4. Archus Orthopedics Performs First Facet Replacement Procedure With an Artificial Disc
5. Facet joint effusion and interspinal ligament edema: major sources of lower back pain
6. TruFUSE(R) Minimally Invasive Facet Fusion Procedure Tops 3,000 Spinal Levels
7. Facet Solutions, Inc. Completes Combination Facet Joint and Disc Replacement Study
8. Facet Solutions, Inc. Appoints Industry Veteran to Board of Directors
9. Facet Solutions, Inc. Expands Executive Management Team
10. Journal of Alzheimers Disease special issue explores multifaceted aspects of AD
11. Facet Solutions AFRS(TM) Implant Demonstrates Positive Clinical Results After One Year Follow Up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... HealthDay Reporter MONDAY, ... should be the first choice of birth control for ... Pediatrics state. Although most U.S. teens opt for ... contraception -- intrauterine devices (IUDs) and contraceptive implants -- ... And they should be the "first-line" choices for teenage ...
(Date:9/30/2014)... 2014 Houstonians seeking the latest information ... visit on the Internet. Paul Vitenas, JR. M.D., ... cosmetic surgeons, has launched a new website to better ... Botox Cosmetic services. The new website can ... to the new website, Botox Cosmetic is a non-surgical ...
(Date:9/30/2014)... 2014 Thanks to generous ... Children’s Oral Health Foundation: America’s ToothFairy® (NCOHF) ... non-profit clinical partners. These organizations are part ... comprehensive educational, preventive and treatment services for ...     Just Kids Dental: $25,000 America's ...
(Date:9/30/2014)... News) -- For millions of overweight Americans, regular exercise ... threat of type 2 diabetes. However, a new ... some than for others, depending on their genes. ... not be as effective for everyone when it comes ... expert, Dr. Ruth Loos, director of the Genetics of ...
(Date:9/30/2014)... California (PRWEB) September 30, 2014 The ... to reach USD 38.75 billion by 2020 at an ... to a new study by Grand View Research, Inc. ... due to lifestyle habits such as excessive alcohol consumption ... organ failure rates is expected to serve this market ...
Breaking Medicine News(10 mins):Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 2Health News:Pediatricians Endorse IUDs, Implants for Teen Birth Control 3Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 2Health News:Dr. Paul Vitenas Launches New Website To Showcase The Benefits Of Botox Cosmetic 3Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 2Health News:America's ToothFairy Awards More Than $150,000 in Grants to Save Young Smiles 3Health News:Can Exercise Prevent Type 2 Diabetes? Your Genes May Be Key 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 2Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 3Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 4Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 5Health News:Global Artificial Organ & Bionics Market Is Expecting Growth At CAGR Of 40.0% In Brain Bionics Segment From 2014 To 2020: Grand View Research, Inc. 6
... , , WASHINGTON, July 20 ... of the people who were infected with the virus were able ... others. Recent studies have begun to unravel the cause of this ... have a unique survival advantage if they have both a low ...
... , , , BEDFORD, Mass., ... leader in tubing-free insulin pump technology with its OmniPod(R) Insulin Management ... quarter 2009 on Tuesday, August 4, 2009 after the close of ... will also host a conference call at 5:00 p.m. Eastern Time ...
... , PORTLAND, Ore. July 20 Studies ... for heart disease, stroke, and delivery of premature or low birth-weight babies. ... without dental insurance - nearly twice the rate of people without medical ... care more accessible to people, Regence Life and Health ...
... growth, metastasis, researchers say , MONDAY, July 20 (HealthDay ... may contribute to aggressive breast cancer, new research shows. ... profiles" of breast cancer tumors, researchers from the Genome ... be implicated in the development of breast cancer. , ...
... , , GREENFIELD, Wis., July ... one-of-a-kind online nutritional service and meal-planning program for cancer patients. ... www.therapeasecuisine.com . Founded by cancer survivors, the program ... registered dietitians. It is available to cancer patients and health ...
... ,The team, led by Professor Matthias Mann ... of Copenhagen and the Max Planck Institute for Biochemistry in ... "This is more than just a technological achievement, ... by a factor of six, and it gives us for ...
Cached Medicine News:Health News:Genetic Variation Associated With Survival Advantage in African Americans With HIV 2Health News:Genetic Variation Associated With Survival Advantage in African Americans With HIV 3Health News:Genetic Variation Associated With Survival Advantage in African Americans With HIV 4Health News:Insulet Corporation to Report Second Quarter 2009 Financial Results on Tuesday, August 4, 2009 2Health News:More Americans Have Cell Phones Than Dental Coverage 2Health News:New Gene May Signal Aggressive Breast Cancer 2Health News:Cancer Survivors Launch New Company, TherapEase Cuisine 2
(Date:9/30/2014)... is evident from the industry players that as a whole ... to the lack of promotional activities to make consumers aware ... acids. Among omega-3 ingredient sources algal oil is expected to ... vegetarian population in India . ... in growth stage of its lifecycle. Omega-3 fatty acids have ...
(Date:9/30/2014)... CytRx Corporation (NASDAQ: CYTR ... in oncology, today announced the initiation of a ... to topotecan in subjects with extensive-stage small cell ... refractory to prior chemotherapy. Aldoxorubicin is CytRx,s modified ... has received Orphan Drug Designation for the treatment ...
(Date:9/29/2014)... SAN DIEGO , 29 septembre ... désignée Daiichi Sankyo) (TSE : 4568) et Ambit Biosciences ... d,un accord de fusion définitif en vertu duquel ... actions ordinaires en circulation d,Ambit Biosciences à 15 ... d,une offre publique d,achat qui sera suivie d,une ...
Breaking Medicine Technology:Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5Daiichi Sankyo va acquérir Ambit Biosciences 2Daiichi Sankyo va acquérir Ambit Biosciences 3Daiichi Sankyo va acquérir Ambit Biosciences 4Daiichi Sankyo va acquérir Ambit Biosciences 5Daiichi Sankyo va acquérir Ambit Biosciences 6Daiichi Sankyo va acquérir Ambit Biosciences 7Daiichi Sankyo va acquérir Ambit Biosciences 8Daiichi Sankyo va acquérir Ambit Biosciences 9
... HealthCare presented results from a global Phase II study ... detection of cerebral beta-Amyloid plaques, at the 19th World ... of the Phase II study was to investigate the ... clinical diagnosis of probable Alzheimer,s disease and Healthy Volunteers ...
... ADA,s 2009 Convention -- When Shawnae Jebbia won the ... a fairytale career. She appeared at events throughout the world, ... But Shawnae,s world unexpectedly changed when she was diagnosed with ... adventure, she had a difficult time understanding and accepting the ...
Cached Medicine Technology:Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 2Bayer HealthCare Presents Florbetaben Phase II Study Results at World Congress of Neurology 3Former Miss USA Shawnae Jebbia Shines with Siemens Pure 2Former Miss USA Shawnae Jebbia Shines with Siemens Pure 3
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
This is a single-action instrument that features a spring handle....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
The Snap-In Snap-Out-II Tip Inserts offer a large variety of configurations....
Medicine Products: